Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CJC-1295 (with DAC) | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 2 mg administered once weekly via subcutaneous injection. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks between cycles. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.
Research indicates 2 mg administered once weekly via subcutaneous injection.
Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.
12-24 week cycles with 4-8 week breaks between cycles.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →